This study was longitudinal, conducted at the Trauma and Burn Centre between January and June 2017. Its purpose was to determine the prevalence of CPE infection among patients admitted to the Burn Intensive Care Unit, and to study their clinical and biological characteristics. Molecular typing of carbapenemases was performed with PCR type GeneXpert. Thirteen patients were infected with 7 episodes of bacteremia, 2 had ventilator acquired pneumonia and 4 catheter infections, with a prevalence of 7% of admissions. The average length of stay in the intensive care unit prior to infection was 12 days. Antibiotic exposure involved 12 of the 13 patients: 9 patients were transferred from other intensive care units. Thirteen and ten patients were respectively exposed to central catheterization and mechanical ventilation. The predominant carbapenemase among the infecting carbapenemase-producing enterobacteriacae strains was NDM carbapenemase (9/15), with a first description of P. stuartii carrying blaNDM strain in Tunisia. One patient died before adapting antibiotic therapy. For the others, 13 adapted bi-antibiotherapies were prescribed. There were five patient deaths from infection, four of whom had received appropriate antibiotic therapy. Imipenem was used each time the MIC was ≤4mg/l, in combination with another antibiotic: amikacin (3/8), colimycin (4/8), or tigecycline (1/8). Three of these prescriptions resulted in death. The prevalence of carbapenemase-producing enterobacterial infections is high among burn patients with a predominance of NDM-type carbapenemase.